13 May, 2017
In other ACADIA Pharmaceuticals news, EVP Terrence O. Moore sold 157,540 shares of the firm's stock in a transaction that occurred on Thursday, February 16th. LLC boosted its stake in shares of ACADIA Pharmaceuticals by 21.3% in the third quarter. Ii Vi Inc now has $1.95 billion valuation. The stock declined 0.84% or $0.05 reaching $5.87 on the news. These shares are worth $311,490 and were traded at $39.65 each. The Return on Investment (ROI) ratio of ACADIA Pharmaceuticals Inc. It has outperformed by 18.10% the S&P500.
Many analysts have provided their estimated foresights on ACADIA Pharmaceuticals Inc. The company has total market capitalization of $3.60B and a total of 122.05M outstanding shares. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. It now has negative earnings.
Were very pleased with our strong start to 2017, The use of NUPLAZID in Parkinsons disease psychosiscontinues to expand as brand awareness among neurologists, psychiatrists, and other healthcare providers grows.
Old National Bancorp increased Select Sector Spdr Tr (XLY) stake by 43,191 shares to 504,698 valued at $41.08 million in 2016Q4. It also upped Aerie Pharmaceuticals Inc (NASDAQ:AERI) stake by 110,000 shares and now owns 610,000 shares. Current ratio was at 10.82 as on March 31, 2017, down from 21.89 on March 31, 2016. The stock has "Buy" rating by JP Morgan on Friday, September 4. (NASDAQ:IIVI) was sold by MATTERA VINCENT D JR on Thursday, February 16.
Investors sentiment decreased to 1.06 in 2016 Q4. Its up 0.15, from 1.02 in 2016Q3. It turned negative, as 42 investors sold ACAD shares while 58 reduced holdings. 48 funds opened positions while 57 raised stakes. Rhenman Prtn Asset Ab reported 70,000 shares. Utah Retirement holds 17,400 shares. First Mercantile Tru Co holds 0.01% of its portfolio in II-VI, Inc. (NASDAQ:ACAD). 1,050 were accumulated by Finance Architects. Granahan Invest Management Ma invested in 1.03M shares. Financial Bank Of America Corporation De holds 392,829 shares or 0% of its portfolio. Van Eck Assocs reported 207,442 shares. The firm's revenue was up 70488.2% compared to the same quarter a year ago. Jane Street Group Ltd Com has invested 0% in ACADIA Pharmaceuticals Inc. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. Therefore 50% are positive. II-VI had 10 analyst reports since August 4, 2015 according to SRatingsIntel.
It's important to get a feel for how any stock is actually valued on the market based on its core numbers. They now have a Dollars 25 price target on the stock. The company was reinitiated on Wednesday, October 19 by Roth Capital.
10/18/2016 - ACADIA Pharmaceuticals Inc. had its "neutral" rating reiterated by analysts at Roth Capital.
ACADIA Pharmaceuticals Inc. has a 50 day moving average of 33.85 and a 200 day moving average of 31.56.
COPYRIGHT VIOLATION WARNING: "ACADIA Pharmaceuticals Inc". (NASDAQ:ACAD) on Friday, January 22 to "Overweight" rating. Needham has "Buy" rating and $49 target. Ladenburg Thalmann reinitiated ACADIA Pharmaceuticals Inc. Perhaps investors are simply anxious that the company's cash hoard is being depleted too rapidly given its torrid rate of spending. Vetr upgraded ACADIA Pharmaceuticals Inc.
03/12/2015 - ACADIA Pharmaceuticals Inc. had its "buy" rating reiterated by analysts at Jefferies. Leerink Partners analysts stated on 04/10/2016 that they launched coverage on this stock with Mkt Perform rating.
About 7,170 shares traded.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has risen 0.12% since September 29, 2016 and is uptrending. It has underperformed by 5.86% the S&P500. Analysts expect ACADIA Pharmaceuticals to post earnings of ($0.73) per share and revenue of $15.17 million for the quarter. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume.
